Chief Executive Officer
Tom joined CoLucid as Chief Executive Officer in 2011. He has more than twenty two years of executive management experience in the life sciences and medical device industry. Mr. Mathers also serves on the Board of Directors for the Biotechnology Industry Organization (BIO), and as founder and chairman of Déclion Holdings and its affiliates.
Prior to CoLucid, Tom served as president and CEO of Peptimmune, Inc.; president and CEO of Cell Based Delivery; vice president and general manager of Cardion AG; vice president of Strategic Development at Genzyme; and held management positions at Snowden-Pencer and Pfizer, Inc.
Tom holds several patents and patents pending and earned his BS in Engineering from the United States Military Academy at West Point, where he was a Dean's List student and three-year starter on the football team as a defensive end. From 1988 to 1991 he served as captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War in the XVIII Airborne Corps.
Chief Financial Officer and Treasurer
Matt joined CoLucid as Chief Financial Officer in February of 2015. Prior to joining CoLucid, Matt was the VP of Finance and Treasurer at AVEO Oncology with responsibility for the Company’s Finance, IT, and Facilities functions. Matt previously worked at Genzyme Corporation, NEN Life Sciences, and Kimberly-Clark Corporation where he held various positions in finance and accounting. He has 18 years of finance experience including 16 in the Biotech/Life Science industry and holds an B.S. in Finance from the University of Tennessee in Knoxville.
Head, Clinical and Regulatory Operations
Bernice (Bernie) Kuca has over twenty years of experience in the pharmaceutical/biotech industry in various clinical operations and clinical project management roles. Her therapeutic experience includes oncology, CNS, antihistamines and anti-infectives. Bernie has had a broad experience from monitoring to clinical leadership as well as providing regulatory and strategic input. Previously at Genetics Institute, Praecis and Sepracor she was a key clinical contributor on products going from INDs to successful NDAs. Bernie has led multi-site, multi-country studies completing them on time and on budget and has presented at industry sponsored conferences on managing relationships with CROs. Known for being the clinical project manager on Sepracor’s sleep medicine, Lunesta® she provided leadership and management of 4 project teams within a CRO as well as multiple vendors, initiating and completing 25 studies (Phase 1 to Phase 3) in 3 years and filing a successful NDA. While at Oscient Bernie led clinical operations and oversaw a post-NDA required Phase 4 study and a multi-country Phase 3B study contributing to an S-NDA.
Bernie has a Bachelor’s degree in Biology from the State University of New York at Buffalo, a Master’s of Science in Applied Anatomy and Physiology from Boston University and a Graduate Certificate of Special Studies in Administration and Management from Harvard University Extension School. Bernie serves on the Board of Directors and Executive Committee of Can Do MS, a National non-profit.
Secretary and Legal Counsel
Dan Boeglin is a partner with Faegre Baker Daniels LLP. He has represented leading pharmaceutical, medical device and biotechnology companies in mergers and acquisitions, corporate partnering, joint venture, strategic investment, licensing, distribution and other transactions. Dan serves as outside general counsel to a number of emerging life sciences companies. He is co‑leader of the firm’s life sciences industry team. Dan is recognized as a leader in corporate and biotechnology law in The Best Lawyers in America and Chambers USA: America’s Leading Lawyers for Business.
Dan is a 1982 graduate of the Indiana University Kelley School of Business and a 1985 graduate of the University of Virginia School of Law. He is a former President of the Kelley School of Business Alumni Association and a former Board member of the Johnson Center for Entrepreneurship and Innovation.
Head, Business Development and Strategy
Linda has over 30 years of experience in the healthcare industry, having served as Vice President of Global Business Development for Aventis in addition to R&D, finance, and commercial positions for its predecessor companies. She provided transaction and strategic advice to client companies as Vice President of Business Development for Clearview Projects, a business development and strategy advisory firm, and she assisted with the identification, evaluation, formation and management of portfolio companies as Executive in Residence at Care Capital, LLC, a venture capital firm. She continues to advise clients as President and Founder of LLH Associates, LLC.
Linda serves on the Springboard Life Sciences Council and is active with the Licensing Executives Society. Professional awards include TWIN (Tribute to Women in Industry) and the Donald E. Francke Award (Drug Information Society). She has served on the Kansas University School of Pharmacy Advisory Council, as President of the Kansas Society of Hospital Pharmacists (KSHP), and on the Board of KSHP.
Prior to joining the pharmaceutical industry, Linda was Adjunct Associate/Assistant Professor of Pharmacy Practice and Director of Drug Information Services for the University of Kansas (KU) School of Pharmacy and Kansas University Medical Center. She received an MS in Hospital Pharmacy from KU and holds an MBA from Rockhurst College and a CLP from the Licensing Executive Society.
Head, Pharmaceutical Operations
Dr. Ray Skwierczynski joins CoLucid with more than 25 years of experience in pharmaceutical operations. His responsibilities include drug substance and drug product manufacturing, analytical, formulation, and both clinical trial and commercial supply chain. Previously, Dr. Skwierczynski served as Senior Director, Pharmaceutical Technology R&D Laboratory at Takeda Pharmaceuticals (formerly Millennium Pharmaceuticals) where he led departments of scientists and engineers responsible for all aspects of small-molecule formulation and analytical development from discovery to commercialization for oral and IV routes of delivery. Dr. Skwierczynski contributed to the late-stage development of ixazomib and alseritib, where he established development and regulatory strategies for pre-clinical development through registration related to pharmaceutical operations. Prior to Takeda, Dr. Skwierczynski held positions of increasing responsibility with 3M Pharmaceuticals and Roche Carolina. Dr. Skwierczynski also serves as a member of an Expert Committee for the United States Pharmacopeia.
Ray earned his Bachelor of Science at the University of Wisconson - Eau Claire, his Masters of Science and Doctorate in Pharmaceutics at the University of Wisconsin.